Product Usage: This PRODUCT IS INTENDED AS A RESEARCH CHEMICAL ONLY. This designation allows the use of research chemicals strictly for in vitro testing and laboratory experimentation only. All product information available on this website is for educational purposes only. Bodily introduction of any kind into humans or animals is strictly forbidden by law. This product should only be handled by licensed, qualified professionals. This product is not a drug, food, or cosmetic and may not be misbranded, misused or mislabeled as a drug, food or cosmetic
Hexarelin
Hexarelin
$51.00 – $67.00Price range: $51.00 through $67.00
Research-grade Hexarelin Acetate (Examorelin), a synthetic hexapeptide (His-D-2-Methyl-Trp-Ala-Trp-D-Phe-Lys-NH₂), designed for controlled investigations of ultra-potent GH release, GHS-R1a/CD36 dual agonism, cardioprotection, and appetite-independent GH pulsatility.
Hexarelin is widely regarded as the most powerful synthetic growth hormone secretagogue (GHS) ever developed. This second-generation hexapeptide features a D-2-methyl-tryptophan substitution that dramatically increases metabolic stability and receptor affinity, producing GH pulses up to 10–15× baseline — stronger than GHRP-6 and GHRP-2 while also uniquely binding CD36 receptors for direct cardioprotective effects. Originally advanced to Phase II for GH deficiency and congestive heart failure, it remains the gold-standard research tool for maximum GH stimulation and cardiac repair studies. This research-grade lyophilized powder is synthesized under strict quality controls and provided with full analytical documentation.
Key Scientific Features
- High-purity Hexarelin Acetate (≥ 98% by HPLC/MS, acetate salt form)
- Verified hexapeptide sequence with D-2-Me-Trp modification: His-D-2-Me-Trp-Ala-Trp-D-Phe-Lys-NH₂
- Lyophilized formulation for maximum long-term stability
- Full Certificate of Analysis (COA) with HPLC, MS, and amino acid analysis
- Manufactured in GMP-aligned, ISO-compliant facilities
- Ideal for maximum GH pulsatility, GHS-R1a/CD36 signaling, and cardioprotection research
Research-Referenced Attributes (Based on scientific literature; not intended as therapeutic claims.)
- Most potent GHRP: single 100 µg/kg dose → peak GH 10–15× baseline in humans
- Unique CD36 receptor binding → direct cardioprotective (reduces infarct size 40–60% in ischemia models)
- Stronger GH release than GHRP-6/GHRP-2 with similar ACTH/cortisol elevation
- Increases cardiac output and left-ventricular ejection fraction in heart failure models
- Synergistic with GHRH for 10–20× amplified GH pulses
- Valuable in GH deficiency, post-MI repair, cachexia, and extreme performance physiology research
Why Researchers Choose Nationwide Peptides Hexarelin Acetate
- Exact clinical-research sequence with D-2-methyl-Trp modification
- Highest documented GH-releasing and cardioprotective potency among GHRPs
- Transparent analytical data (HPLC >98%, MS confirmation)
- Trusted by cardiology, endocrinology, and extreme physiology laboratories
- Competitive research pricing with bulk options
Storage & Handling
- Store lyophilized powder at –4 °F (long-term) or 39.2 °F (short-term)
- Store in a tightly sealed container and protect from light, moisture, air exposure, and elevated temperatures.
- Reconstitute only with bacteriostatic water or sterile saline (typical concentration 2–5 mg/mL)
- Reconstituted solutions stable at 39.2 °F for up to 4 weeks; avoid repeated freeze-thaw cycles
- Use appropriate PPE and aseptic technique
Peptide Research
- aGhigo E et al. (1996) Dose-response in humans [PMID: 7957536, https://pubmed.ncbi.nlm.nih.gov/7957536/].
- Locatelli V et al. (2014) Cardiovascular action review [PMC: PMC4178518, https://pmc.ncbi.nlm.nih.gov/articles/PMC4178518/].
- Arvat E et al. (1997) No interaction with CRH/AVP [PMID: 9430449, https://pubmed.ncbi.nlm.nih.gov/9430449/].
- Ghigo E et al. (1998) Pubertal response [PMID: 9801989, https://pubmed.ncbi.nlm.nih.gov/9801989/].
- Deghenghi R et al. (1996) Mechanism in rats [PMID: 8921832, https://pubmed.ncbi.nlm.nih.gov/8921832/].
- Benso A et al. (2003) Lipid aberrations in mice [PMC: PMC5659698, https://pmc.ncbi.nlm.nih.gov/articles/PMC5659698/].
- Arvat E et al. (1996) Acromegaly/hyperprolactinemia [PMID: 8706295, https://pubmed.ncbi.nlm.nih.gov/8706295/].
- Loche S et al. (1995) Short children [PMID: 8548949, https://pubmed.ncbi.nlm.nih.gov/8548949/].
- Deghenghi R et al. (1996) Intranasal in children [PMID: 7852535, https://pubmed.ncbi.nlm.nih.gov/7852535/].
- Cassoni P et al. (2006) Neuroblastoma SOD1-G93A protection [PMC: PMC9863688, https://pmc.ncbi.nlm.nih.gov/articles/PMC9863688/].
COA
